Last C$3.76 CAD
Change Today +0.04 / 1.08%
Volume 11.4K
I On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

intellipharmaceutics interna (I) Snapshot

Open
C$4.03
Previous Close
C$3.72
Day High
C$4.03
Day Low
C$3.76
52 Week High
11/20/13 - C$6.70
52 Week Low
11/7/13 - C$1.72
Market Cap
87.7M
Average Volume 10 Days
35.4K
EPS TTM
C$-0.45
Shares Outstanding
23.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELLIPHARMACEUTICS INTERNA (I)

Related News

No related news articles were found.

intellipharmaceutics interna (I) Related Businessweek News

No Related Businessweek News Found

intellipharmaceutics interna (I) Details

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorders; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorders, and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as Pristiq, a tablet for depression. The company is also developing Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for neuropathic pain. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

38 Employees
Last Reported Date: 02/18/14

intellipharmaceutics interna (I) Top Compensated Officers

Co-Founder, Chairman, Chairman of Scientific ...
Total Annual Compensation: $509.7K
President, Chief Operating Officer, Principal...
Total Annual Compensation: $509.7K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $244.1K
Vice President of Legal Affairs & Licensing, ...
Total Annual Compensation: $141.6K
Compensation as of Fiscal Year 2013.

intellipharmaceutics interna (I) Key Developments

IntelliPharmaCeutics International Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended May 31, 2014

IntelliPharmaCeutics International Inc. reported unaudited consolidated earnings results for the second quarter and six months ended May 31, 2014. For the quarter, the company reported a net loss of $3,140,275, or $0.14 per common share, compared with $1,781,662, or $0.09 per common share a year ago. The net loss for the three months ended May 31, 2014 is attributed to the ongoing R&D and selling, general and administrative expenses, including an increase in stock-based compensation expense, payment of bonuses to certain management employees, and increased salaries to certain non-management employees, partially offset by licensing revenue and milestone revenue. Loss from operations was $3,065,625 compared with $1,786,512 a year ago. Net cash flows from operating activities were $918,965 against net cash flows used in operating activities of $1,754,922 a year ago. The increase in net cash flows provided from operating activities was due to the receipt of $2.8 million relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by Par for the 15 and 30 mg strengths of the drug product for the period January 1, 2014 to March 31, 2014, and $0.4 million as a milestone payment tied to the achievement of product being either the only generic in the market or having only one generic competitor, under the license and commercialization agreement with Par. Purchase of property and equipment was $217,319 against $64,123 a year ago. Revenue was $1,478,942. The revenue in the three months ended May 31, 2014 derived principally from commercial sales of its first product, 15 and 30 mg strengths of dexmethylphenidate hydrochloride extended-release capsules (generic Focalin XR(R)). For the six months, the company reported net loss of $938,840, or $0.04 per common share, compared with $3,121,794, or $0.17 per common share a year ago. Loss from operations was $820,337 compared with $4,050,796 a year ago. Net cash flows from operating activities were $1,136,089 against net cash flows used in operating activities of $3,183,803 a year ago. Purchase of property and equipment was $282,879 against $101,187 a year ago. Revenue was $6,160,000.

IntelliPharmaCeutics International Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

IntelliPharmaCeutics International Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

Intellipharmaceutics International Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended February 28, 2014

Intellipharmaceutics International Inc. announced unaudited consolidated earnings results for the first quarter ended February 28, 2014. For the quarter, the company income from operations was $2.2 million compared with loss from operations of $2.3 million for the three months ended February 28, 2013. The company recorded net income of $2.2 million, or $0.09 per diluted common share, compared with a loss of $1.3 million, or $0.07 per diluted common share for the three months ended February 28, 2013. The net income is attributed to the licensing revenue and milestone revenue. For the three months ended February 28, 2013, the net loss was attributed to the ongoing R&D and selling, general and administrative expenses, partially offset by the gain in fair value adjustment of derivative liabilities. Net cash flows provided from operating activities increased to $0.2 million as compared to net cash flows used in operating activities of $1.4 million for the three months ended February 28, 2013. The increase in cash provided was due to the receipt by the company of approximately $3.1 million as its first payment relating to commercial sales of its products by Par. Revenue was $4,681,058. Purchase of property and equipment was $65,560 against $37,064 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I:CN C$3.76 CAD +0.04

I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,481 GBp -64.50
Durect Corp $1.60 USD -0.01
Lupin Ltd 1,361 INR -55.00
Torrent Pharmaceuticals Ltd 885.00 INR +10.20
View Industry Companies
 

Industry Analysis

I

Industry Average

Valuation I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLIPHARMACEUTICS INTERNA, please visit www.intellipharmaceutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.